Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices

Journal of Clinical Medicine

Mohammadbagher Ziari¹  NicholasJ. Salgia²  SumantaKumar Pal²  Kelly Yap³  ErrolJ. Philip⁴ 

[1] Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Corona, CA 92879, USA;Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91107, USA;Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, South Pasadena, CA 91030, USA;University of California San Francisco School of Medicine, San Francisco, CA 94143, USA;

关键词: renal cell carcinoma;    team medicine;    translational research;    community practice;    clinical trials;   

DOI  :  10.3390/jcm9051508

来源: DOAJ

【 摘 要 】

The treatment of metastatic renal cell carcinoma (mRCC) has rapidly evolved; however, the progress made in the field is heavily contingent upon timely and efficient accrual to clinical trials. While a substantial proportion of accrual occurs at tertiary care centers, community sites are playing an increasing role in patient recruitment. In this article, we discuss strategies to optimize collaborations between academic and community sites to facilitate clinical research. Further, as the role of biomarker discovery has become increasingly important in tailoring therapy, we will discuss opportunities to bridge diverse accrual sites for the purpose of translational research.

【 授权许可】

Unknown